Evidence map›Paper›PMID 34164774›Full record

ArticleHuman cell2021

Circular RNA circ-CHI3L1.2 modulates cisplatin resistance of osteosarcoma cells via the miR-340-5p/LPAATβ axis.

Zehua Zhang, Qiang Zhou, Fei Luo, Rui Zhou, Jianzhong Xu, Jun Xiao, Fei Dai, Lei Song

Abstract read
PubMed Publisher
In one paragraph

Article in Human cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Osteosarcoma in a ceRNET perspective.Journal of biomedical science · 2024
    Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. miR-340-5p mediates the therapeutic effect of mesenchymal stem cells on corneal neovascularization.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022
    Article
  14. Review
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Zehua Zhang *Department of Orthopaedics, First Affiliated Hospital, Army Medical University, No. 30 Gaotanyanzheng street, Chongqing, 400038, China.
Qiang Zhou *Department of Orthopaedics, Third Affiliated Hospital, Medical University of Chongqing, Chongqing, 401120, China.
Fei LuoDepartment of Orthopaedics, First Affiliated Hospital, Army Medical University, No. 30 Gaotanyanzheng street, Chongqing, 400038, China.
Rui ZhouDepartment of Orthopaedics, First Affiliated Hospital, Army Medical University, No. 30 Gaotanyanzheng street, Chongqing, 400038, China.
Jianzhong XuDepartment of Orthopaedics, First Affiliated Hospital, Army Medical University, No. 30 Gaotanyanzheng street, Chongqing, 400038, China.
Jun XiaoDepartment of Orthopaedics, First Affiliated Hospital, Army Medical University, No. 30 Gaotanyanzheng street, Chongqing, 400038, China.
Fei DaiDepartment of Orthopaedics, First Affiliated Hospital, Army Medical University, No. 30 Gaotanyanzheng street, Chongqing, 400038, China. david-feifei@163.com.
Lei SongDepartment of Orthopaedics, First Affiliated Hospital, Army Medical University, No. 30 Gaotanyanzheng street, Chongqing, 400038, China. cobisonglei@163.com.ORCID http://orcid.org/0000-0002-0162-0282
Army Medical University · CN

Funding

Clinical Science Foundation of Army Medical University no. 2018XLC3018
6 · The paper itself

Abstract

Resistance to chemotherapy drugs is a major factor affecting the surgical outcome and prognosis of osteosarcoma patients. Circular RNAs (circRNAs) play an important role in tumor resistance to chemotherapy. In the present study, we aimed to investigate the role and mechanism of circRNA circ-chitinase 3-like 1.2 (CHI3L1.2) in resistance to cisplatin chemotherapy in osteosarcoma. We found that circ-CHI3L1.2 levels were higher in cisplatin-resistant cells than in their parent cells. circ-CHI3L1.2 knockdown decreased the half-maximal inhibitory concentration (IC

Indexed as

AcyltransferasesAntineoplastic AgentsBone NeoplasmsCell Line, TumorChitinase-3-Like Protein 1ChitinasesCisplatinDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansMicroRNAsOsteosarcoma2-acylglycerophosphate acyltransferaseAcyltransferasesAntineoplastic AgentsCHI3L1 protein, humanCHI3L2 protein, humanChitinase-3-Like Protein 1ChitinasesCisplatinMicroRNAsMIRN340 microRNA, humanCirc-CHI3L1.2Cisplatin resistanceCompetitive endogenous RNALPAATβmiR-340-5p

Identifiers

PMID34164774
OpenAlexW3174941789

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.